p38 MAPK

MAPK

p38 MAPK

p38 MAPK Isoform Specific Products:

p38 MAPK Related Products (565)
Recombinant Proteins (3)
Antibodies (20)
p38 MAPK Isoform Comparison

By Effects:	Control (1) Inhibitors (414) Agonists (3) Degrader (1) Activators (94) Modulators (5) p53 Inhibitor (1) Inducers (8)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-N0404R

Sinigrin (Standard)	Inhibitor
Sinigrin (Standard) is the analytical standard of Sinigrin. This product is intended for research and analytical applications. Sinigrin is a major glucosinolate present in plants of the Brassicaceae family. Sinigrin inhibits early-stage adipogenesis of 3T3-L1 adipocytes through the AMPK and MAPK signaling pathways. Sinigrin has potent anti-oxidant, anti-tumor and anti-inflammatory effects.

HY-111164

CBS-3595	Inhibitor
CBS-3595 is a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 with anti-inflammatory and anti-allodynic activities. CBS-3595 reduces the production of the proinflammatory cytokine IL-6 and increases the levels of the anti-inflammatory cytokine IL-10 in rats. CBS-3595 reduces paw oedema formation in the Complete Freund’s adjuvant (CFA) (HY-153808)-induced arthritis rat model. CBS-3595 is promising for research of autoimmune diseases.

HY-N0591R

Dehydrocostus Lactone (Standard)	Inhibitor
Dehydrocostus Lactone (Standard) ((-)-Dehydrocostus lactone (Standard)) is the analytical standard of Dehydrocostus Lactone (HY-N0591). This product is intended for research and analytical applications. Dehydrocostus Lactone is a natural sesquiterpene that can be isolated from Saussurea lappa. Dehydrocostus Lactone has multiple activities such as anti-inflammatory, antibacterial, anti-tumor, and immunomodulatory effects. Dehydrocostus Lactone has an MIC of 2 µg/mL against Mycobacterium tuberculosis. Dehydrocostus Lactone can also inhibit the killing activity of cytotoxic T lymphocytes and induce apoptosis in tumor cells.

HY-13703

Nimustine	Inhibitor
Nimustine is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity.

HY-136794

SB-284851-BT	Inhibitor
SB-284851-BT is an inhibitor of BRD4/p38α/BRDT. SB-284851-BT inhibits BRD4-BD1 (IC₅₀=1.7 µM), p38α (K_d=0.47 nM), BRDT (1) (IC₅₀=18 µM) and BRD4 (1)(IC₅₀=3.7 µM). SB-284851-BT reduces IL-8 production by inhibiting p38α, as well as inhibiting BRD4 to down-regulates c-Myc and NF-κB gene pathways in cancer. SB-284851-BT can combined with the bromine domain and extra terminal (BET).

HY-14654C

Aspirin calcium	Activator
Aspirin calcium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC₅₀ values of 5 and 210 μg/mL, respectively. Aspirin calcium induces apoptosis. Aspirin calcium inhibits the activation of NF-κB. Aspirin calcium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis.

HY-163429

J-1149	Inhibitor
J-1149 is a potent ALK5 inhibitor, with an IC₅₀ value of 0.017 μM. J-1149 also shows weak p38α MAP kinase inhibitory activity, with an IC₅₀ value of 0.435 μM. J-1149 can be used for liver fibrosis research.

HY-18759

BMS-751324	Inhibitor
BMS-751324 is a p38α MAPK inhibitor. BMS-751324 equips a precursor of carbamyl-methyl linkage, containing esters and phosphate functional groups derived from hydroxyphenylacetic acid (HPA). BMS-751324 effectively inhibits foot swelling and LPS-induced TNFα production in an arthritic rat model.

HY-P10852

TAT-MKK3b	Inhibitor
TAT-MKK3b is a p38 peptide inhibitor. TAT-MKK3b can inhibit p38 phosphorylation. TAT-MKK3b has renal targeting, ROS-scavenging, and ferroptosis-mitigating capabilities. TAT-MKK3b improves acute kidney injury and its progression to chronic kidney disease.

HY-157211

Anti-inflammatory agent 66	Inhibitor
Anti-inflammatory agent 66 (compound 8) is a pterostilbene derivative with anti-inflammatory activity. Anti-inflammatory agent 66 inhibits pro-inflammatory cytokines by blocking the LPS-induced NF-κB/MAPK signaling pathway and effectively alleviates DSS-induced acute colitis in mice.

HY-116836

p38α inhibitor 7	Inhibitor
p38α inhibitor 7 (compound 1) is an effective p38α inhibitor with oral efficacy and generally favorable pharmacokinetic properties.

HY-120796

MW108 hydrochloride	Inhibitor
MW108 (MW01-11-108SRM) hydrochloride is a selective and CNS-penetrant p38αMAPK inhibitor with a K_i of 114 nM. MW108 hydrochloride ameliorates beta-amyloid induced synaptic and cognitive dysfunction.

HY-P2319

OVA-E1 peptide	Activator
OVA-E1 peptide, is an antagonist variant of SIINFEKL [OVA (257-264). OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.

HY-162641

AF-45	Inhibitor
AF-45 inhibits IRAK4 and IRAK1, with IC₅₀s of 128 nM and 1765 nM. AF-45 inhibits the release of IL-6 and TNF-α in macrophages, with IC₅₀s of 0.53-1.54 μM and 0.6-2.75 μM. AF-45 is also an inhibitor for NF-κB/MAPK signaling pathway. AF-45 exhibits anti-inflammatory activities against DSS-induced ulcerative colitis and Lipopolysaccharide (HY-D1056)-induced acute lung injury in mouse model. AF-45 exhibits good pharmacokinetic characteristics in rat models.

HY-N1904

4′-Hydroxywogonin	Inhibitor
4′-Hydroxywogonin (8-Methoxyapigenin), a flavonoid, could be isolated from a variety of plants including Scutellaria barbata and Verbena littoralis. 4′-Hydroxywogonin has anti-inflammatory activity via TAK1/IKK/NF-κB, MAPKs and PI3/AKT signaling pathways. 4′-Hydroxywogonin inhibits angiogenesis by disrupting PI3K/AKT signaling. 4′-Hydroxywogonin inhibits cell proliferation and induces apoptosis.

HY-108644

SB 706504	Inhibitor
SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides (HY-D1056)-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD).

HY-N0498R

Nitidine chloride (Standard)	Inhibitor
Nitidine (chloride) (Standard) is the analytical standard of Nitidine (chloride). This product is intended for research and analytical applications. Nitidine chloride, a potential anti-malarial lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing apoptosis, inhibiting STAT3 signaling cascade, DNA topoisomerase 1 and 2A, ERK and c-Src/FAK associated signaling pathway. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kB pathway.

HY-168841

p38α-MK2-IN-1	Inhibitor
p38α-MK2-IN-1 (Compound 36) is a p38α-MK2 complex inhibitor (IC₅₀: 5 nM). p38α-MK2-IN-1 has a robust inflammation inhibitory effect and joint repair ability.

HY-171178

DK2403
DK2403 (compound 25) is a MAP2K7 inhibitor (IC₅₀= 0.01 μM). DK2403 can effectively inhibit MAP2K7 without significantly disrupting the larger kinase group and can be used to study childhood T-cell acute lymphoblastic leukemia.

HY-152087

DCZ19931	Inhibitor
DCZ19931 is a potent multi-targeting kinase inhibitor. DCZ19931 has anti-angiogenic effects on ocular neovascularization. DCZ19931 also inhibits ERK1/2-MAPK and p38-MAPK signaling.

Adezmapimod	p38, IC₅₀: 50 nM		p38β2, IC₅₀: 500 nM				99.96%
SB 202190		p38α, IC₅₀: 50 nM	p38β2, IC₅₀: 100 nM				99.89%
Doramapimod	p38 MAP kinase, Kd: 0.1 nM	p38α, IC₅₀: 38 nM	p38β, IC₅₀: 65 nM		p38δ, IC₅₀: 520 nM	p38γ, IC₅₀: 200 nM	99.98%
Adezmapimod hydrochloride	p38, IC₅₀: 50 nM		p38β2, IC₅₀: 500 nM				99.71%
Muramyl dipeptide	p38 MAPK						≥98.0%
Diprovocim	p38 MAPK						98.82%
Naporafenib		p38α, IC₅₀: 2.1 μM					99.86%
Ralimetinib dimesylate		p38α MAPK, IC₅₀: 5.3 nM	p38β MAPK, IC₅₀: 3.2 nM				99.94%
Neflamapimod		p38α, IC₅₀: 10 nM	p38β, IC₅₀: 220 nM				99.32%
Exarafenib	p38 MAPK						99.68%
Skatole	p38						99.97%
Esculin	p38 MAPK						99.47%
Talmapimod		p38α, IC₅₀: 9 nM	p38β, IC₅₀: 90 nM				98.68%
p38 MAPK-IN-1	p38 MAPK, IC₅₀: 68 nM						99.58%
SB 202190 hydrochloride		p38α, IC₅₀: 50 nM	p38β2, IC₅₀: 100 nM				99.66%
Tpl2 Kinase Inhibitor 1	p38, IC₅₀: 180 μM						99.22%
Paris saponin VII	p38						99.96%
AMG-548 dihydrochloride		p38α, Ki: 0.5 nM dog p38α, Ki: 5.0 nM	p38β, Ki: 3.6 nM		p38δ, Ki: 2600 nM	p38γ, Ki: 4100 nM	99.86%
Broussonin E	p38 MAPK						98.18%
Semapimod tetrahydrochloride	p38 MAPK						98.43%
TAK-715		p38α, IC₅₀: 7.1 nM	p38β, IC₅₀: 200 nM		p38δ, IC₅₀: >10 μM	p38γ, IC₅₀: >10 μM	99.76%
Gossypetin	p38 MAP kinase						99.82%
Peimine	p38						99.43%
Dihydrocaffeic acid	p38 MAPK						99.65%
MAPK13-IN-1				MAPK13 (p38δ), IC₅₀: 620 nM			98.93%
Teneligliptin hydrobromide	p38 MAPK						99.99%
NF-κB/MAPK-IN-1	p38						98.42%
Pamapimod		p38α, IC₅₀: 14 nM p38α, Ki: 1.3 nM	p38β, IC₅₀: 480 p38β, Ki: 120 nM				99.92%
UM-164		p38α	p38β				99.15%
Cornuside	p38 MAP kinase						99.99%
SM-7368	p38 MAP kinase						99.77%
Ferulic acid methyl ester	p38						99.95%
EW-7195		p38α, IC₅₀: 1.5 μM					98.84%
Emprumapimod		p38α					99.04%
SR-318		p38α, IC₅₀: 5 nM	p38β, IC₅₀: 32 nM				99.89%
BMS-582949 hydrochloride		p38α MAPK, IC₅₀: 13 nM					98.90%
Isoliquiritin apioside	p38 MAPK						99.87%
MW-150		p38α, Ki: 101 nM					99.89%
MKK7-COV-9	p38 MAP kinase
CK1-IN-1		p38α MAPK, IC₅₀: 73 nM					99.19%
N-Feruloyloctopamine	p38 MAPK						99.91%
R1487 Hydrochloride		p38α, Kd: 0.2 nM	p38β, Kd: 29 nM				99.33%
TA-01	p38 MAP kinase, IC₅₀: 6.7 nM						99.86%
RWJ-67657		p38α, IC₅₀: 1 μM	p38β, IC₅₀: 11 μM				99.75%
JNJ-49095397		p38α				p38γ	99.85%
SJFα		p38α, DC₅₀: 7.16 nM			p38δ, DC₅₀: 299 nM		99.61%
Rotundic acid	p38 MAPK						99.41%
p38α inhibitor 2		p38α MAPK, pIC₅₀: 9.6					98.03%
Anti-inflammatory agent 35	p38 MAPK						99.77%
p38 MAP Kinase Inhibitor III	p38 MAP kinase, IC₅₀: 0.9 μM						98.77%
SD-169		p38α MAPK, IC₅₀: 3.2 nM	p38β MAPK, IC₅₀: 122 nM				99.91%
PF-05381941		p38α, IC₅₀: 186 nM					99.73%
p38 MAP Kinase Inhibitor IV		p38α, IC₅₀: 0.13 μM	p38β, IC₅₀: 0.55 μM		p38δ, IC₅₀: 8.63 μM		98.0%
AMG-548		p38α, Ki: 0.5 nM dog p38α, Ki: 5.0 nM	p38β, Ki: 3.6 nM		p38δ, Ki: 2600 nM	p38γ, Ki: 4100 nM	≥99.0%
SB 220025	p38, IC₅₀: 60 nM						99.90%
p38 MAPK-IN-4	p38, IC₅₀: 35 nM						98.45%
p38α inhibitor 1		p38α					98.91%
AL 8697		p38α, IC₅₀: 6 nM	p38β, IC₅₀: 82 nM				99.83%
Emprumapimod hydrochloride		p38α					≥98.0%
SX 011		p38α, IC₅₀: 9 nM	p38β, IC₅₀: 90 nM		p38δ, IC₅₀: > 300 (Pan)	p38γ, IC₅₀: > 300 (Pan)	99.33%
NR-11c		p38α					99.75%
Sugiol	p38 MAPK						99.88%
MW-150 hydrochloride		p38α, Ki: 101 nM
MW-150 dihydrochloride dihydrate		p38α, Ki: 101 nM
Ralimetinib		p38α MAPK, IC₅₀: 5.3 nM	p38β MAPK, IC₅₀: 3.2 nM
Talmapimod hydrochloride		p38α, IC₅₀: 9 nM	p38β, IC₅₀: 90 nM
Casein kinase 1δ-IN-27		p38α, IC₅₀: 14.8 nM
p38-α MAPK-IN-4		p38α MAPK, IC₅₀: 1.5 μM
Casein kinase 1δ-IN-29		p38α, IC₅₀: 0.041 μM
Halociline	p38 MAP kinase
SJFδ		p38α, DC₅₀: 46.17 nM
p38-α MAPK-IN-5		p38α, IC₅₀: 0.1 nM	p38β, IC₅₀: 0.2 nM		p38δ, IC₅₀: 4100 nM	p38γ, IC₅₀: 944 nM
p38 MAPK-IN-3		p38α MAPK
SB-284851-BT		p38α, Kd: 0.47 nM
J-1149		p38α MAPK
p38α inhibitor 7		p38α
MW108 hydrochloride		p38α MAPK, Ki: 114 nM
p38α-MK2-IN-1		p38α
DCZ19931	p38 MAPK
Lucidone	p38 MAPK
AMG-548 hydrochloride		p38α, Ki: 0.5 nM dog p38α, Ki: 5.0 nM	p38β, Ki: 3.6 nM		p38δ, Ki: 2600 nM	p38γ, Ki: 4100 nM
CHMFL-ABL-053	p38, IC₅₀: 62 nM
Semapimod	p38 MAPK
NDs-IN-1	p38 MAPK
(aS)-PH-797804		p38α, IC₅₀: 26 nM	p38β, IC₅₀: 102 nM
JNK3 inhibitor-5		p38α, IC₅₀: 215.8 nM
Balanophonin	p38
Doramapimod (GMP)		p38α, IC₅₀: 38 nM	p38β, IC₅₀: 65 nM		p38δ, IC₅₀: 520 nM	p38γ, IC₅₀: 200 nM
PF-03715455		p38α, IC₅₀: 0.88 nM	p38β, IC₅₀: 23 nM
SR-302		p38α, IC₅₀: 125 nM
BMS-582949		p38α, IC₅₀: 13 nM
CK1δ-IN-9		p38α, IC₅₀: 0.25 μM	p38β, IC₅₀: 0.78 μM
Cudraflavone B	p38 MAP kinase
p38α inhibitor 4		p38α, IC₅₀: 1.2 μM
Casein kinase 1δ-IN-31		p38α, IC₅₀: 18 nM
p38α inhibitor 8		p38α, IC₅₀: 0.21 μM
p38-α MAPK-IN-10		p38α, IC₅₀: 4 nM

Name
Email *

	Sorry, but the email address you supplied was invalid.

p38 MAPK

p38 MAPK

p38 MAPK Isoform Specific Products:

p38 MAPK Isoform Specific Products:

p38 MAPK Related Products (565)

Recombinant Proteins (3)

Antibodies (20)

p38 MAPK Isoform Comparison

p38 MAPK Related Products (565):